---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-056733"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:42:03.607756+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theravance Q1 net loss narrows to $4.9M; YUPELRI revenue up 15%; all generic litigation settled

## Summary
- YUPELRI collaboration revenue of $17.7M, up 15% YoY; implied 35% share of net sales $21.9M (+7%).
- Net loss $4.9M vs. $13.6M YoY; Non-GAAP net income from operations $0.6M vs. loss of $8.6M.
- Operating expenses down ~20% YoY (ex-restructuring); restructuring on track for ~60% reduction by Q3 2026.
- All Hatch-Waxman YUPELRI litigation resolved; settlement with Mankind Pharma sets licensed launch date April 23, 2039.
- Cash $395M, no debt; Strategic Review Committee evaluating sale or other value-maximizing alternatives.

## SEC filing metadata
- accession: 0001104659-26-056733
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465926056733/0001104659-26-056733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465926056733/tm2613884d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-056733
- JSON: https://secwatch.observer/filing/0001104659-26-056733.json
- Plain text: https://secwatch.observer/filing/0001104659-26-056733.txt

## Source-grounded claims
- claim_id: 485063c3cb43b35521de8a402f4d1f8a1d407be7
  claim: Theravance Biopharma, Inc. reported first quarter of 2026 results: revenue $17.7 million.
  evidence_excerpt: Total revenue for the first quarter of 2026 was $17.7 million, consisting entirely of Viatris collaboration revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465926056733/0001104659-26-056733-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.